PICAROS - Acalabrutinib RWE on 1L CLL in Spain

Active, not recruiting

• Conditions: Chronic Lymphocytic Leukemia

• Registration Number: NCT05999877
• Lead Sponsor: AstraZeneca

Brief Summary

This is a multicenter non-interventional study (NIS) on patients with CLL who have been treated with acalabrutinib for the first time within the year before the first site initiation visit in Spain

Detailed Description

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who have been treated with acalabrutinib for the first time within the year before the first site initiation visit, from approximately 50 Hospitals in Spain. Patients who had already initiated acalabrutinib therapy will be identified by the investigators and offered to participate in the study.

The start of acalabrutinib treatment (index date) must be prior to the first site initiation visit. Therefore, the clinical decision of starting patient on acalabrutinib has independently occurred prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to 3.5 years from the first site initiation visit. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

Study Timeline

• Study First Submitted: 2023-06-29
• Study Start: 2023-07-11
• Study First Submitted QC: 2023-08-10
• Study First Posted: 2023-08-21
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-05
• Last Update Posted: 2025-05-06
• Primary Completion: 2026-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 192

Inclusion Criteria

• Age ≥18 years old at starting acalabrutinib treatment.
• Diagnosis of CLL.
• Start of acalabrutinib treatment (index date) in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit. Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.
• Informed consent (for alive patients).

Exclusion Criteria

• Enrolled in any clinical trial during acalabrutinib treatment.
• Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation.	24 months after treatment initiation.	Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation.; In addition to this outcome measured in the overall population, it will also be assessed by the following factors: 1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression),; 2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV).; 3. cardiovascular comorbidities (yes/no).

Secondary Outcome Measures

Name	Time	Method
Start dose in mg.	At acalabrutinib start date	Acalabrutinib dose at starting treatment, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).
Treatment duration in months.	From acalabrutinib start to acalabrutinib end, assessed up to 3.5 years of prospective study follow-up.	Treatment duration, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).; Baseline patient characteristics associated with treatment duration in multivariate analyses, overall and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).
Adverse events that lead to acalabrutinib dose changes, temporary interruptions, or permanent discontinuation. Adverse events that are considered serious during acalabrutinib treatment. Events of clinical interest.	From acalabrutinib start to acalabrutinib end, assessed up to 3.5 years of prospective study follow-up.	Adverse events that lead to acalabrutinib dose changes, temporary interruptions, or permanent discontinuation.; Adverse events that are considered serious (including fatal events) during acalabrutinib treatment, globally and treatment related (when available).; Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available).They will be described overall and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]).	From the date of first dose of acalabrutinib to the first dose of the next treatment for CLL or death from any cause, whichever came first, assessed up to 3.5 years of prospective study follow-up.	TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause \[i.e. deaths are not censored\]), overall and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause).	From the date of first dose of acalabrutinib to death from any cause, whichever came first, assessed up to 3.5 years of prospective study follow-up.	OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).
Patients with acalabrutinib dose reductions (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %).	From acalabrutinib start to acalabrutinib end, assessed up to 3.5 years of prospective study follow-up.	Acalabrutinib dose reductions, temporary interruptions, and permanent discontinuations, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib.	From acalabrutinib start to acalabrutinib end, assessed up to 3.5 years of prospective study follow-up.	Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression).; The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time: PDC (%)=(No.days covered)/(No.days of interest)×100

Trial Locations

Locations (1)

Research Site; 🇪🇸 Murcia, Region De Murcia, Spain